The vaccine adjuvants market is projected to reach USD 1.6 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 1.7% during the forecast period. Growth in the vaccine adjuvants market can be attributed to factors such as the collaborations and partnerships among market players for the development of vaccine adjuvants and an increasing number of COVID-19 vaccines in the development pipeline
Vaccine adjuvants are ingredients added to vaccines to enhance their effectiveness. Adjuvants are used to increase the body’s immune response to the vaccine and help provide a longer-lasting immunity. They are an important part of vaccine development, helping to make vaccines safer and more effective.
The growth of the vaccine adjuvants market is mainly driven by the increasing prevalence of infectious diseases and rising public and private investments in vaccine development. Furthermore, the market is driven by the increasing number of clinical trials and the increasing demand for combination vaccines, which require adjuvants. In addition, the growing focus of government and private organizations on immunization programs is also driving the market growth.
Get a sample of the report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894
Top Lading Players: GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia)
Some Key Highlights from the Report:
- The global vaccine adjuvants market is projected to reach USD 1.6 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 1.7% during the forecast period of 2022 to 2027
- Growing awareness among the public in terms of preventive healthcare, increasing government initiatives to promote vaccination, and rising prevalence of infectious diseases are the major factors driving the market growth.
- The aluminium salts segment held the largest market share, owing to their wide use in the production of various vaccines.
- The pandemic of coronavirus (COVID-19) has been creating a huge demand for vaccines and related products, which is expected to drive the market for the forecast period.
- North America held the largest market share, owing to the increasing adoption of vaccines and immunizations, rising government initiatives to promote vaccination, and technological advancements.
Segments covered in the report:
By Product
- Adjuvant Emulsions
- Pathogen Components
- Saponin-baased adjuvants
- Particulate Adjuvants
- Other Adjuvants
By Route of Administration
- Intramuscular
- Subcutaneous
- Other Route of Administration
By Disease Type
- Infectious Diseases
- Cancer
- Others
By Application
- Research Applications
- Commercial Applications
By Application Category
- Human Vaccine Adjuvants
- Veterinary Vaccine Adjuvants
Ask for Customize Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894
Regional Outlook:
- North America (U.S.A., Canada, Mexico)
- Europe (Italy, U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
- Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key Questions Addressed in the Report:
- What are the dominating factors that are influencing the growth of the industry?
- In the forecast period, which market segment is expected to rise the most?
- What are the risks and challenges that the industry is facing?
- In the coming years, which area is projected to dominate the market?
- Who are the major players in the market?
- What kind of strategic business plans have they made?
Get More Insights @ https://www.globenewswire.com/en/news-release/2022/09/12/2514257/0/en/Vaccine-Adjuvants-Market-worth-1-6-billion-by-2027-Exclusive-Report-by-MarketsandMarkets.html
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com